

### **REMARKS**

The undersigned wishes to thank the Examiner for the courtesy of the interview held on September 24, 2002, to which the present remarks are responsive.

Claims 25-43 are canceled and claims 44-94 are added. The claims are supported in the original specification and claims. Claims 44, 60 and 76 are directed to polynucleotide sequences that encode a light chain variable region and/or a heavy chain variable region of an LL2 monoclonal antibody, and are supported in the specification on page 5, lines 20-23, Figures 3A and 3B and Examples 2-4. Additionally, the language in these claims that recites that the LL2 mAb or antigen binding fragment thereof "...retains the immunoreactivity of the mLL2" is supported on page 19, lines 1-5, page 32, lines 19-25 and page 36, lines 8-11. The claims directed to amino acid substitutions in the FRs are supported on page 6, lines 6-13 and page 22, lines 18-23. The vector and host cell claims and method of producing the light and/or heavy variable chains are supported on page 10, lines 16 and page 16, lines 10-page 17, line 36.

As discussed at the interview, certain corrections to the sequence information in this application are needed. Applicants have not amended the specification to conform with these requested changes but hold such amendments in abeyance until the Examiner indicates that the requested changes are supported and will be entered. In these remarks, applicants provide two independent bases of support for these corrections:

#### **Support based on originally filed text, including identified restriction sites, cited references, and vector diagrams**

The originally filed specification describes the steps used to construct the sequences of the claimed antibodies and their DNAs with reference to various restriction sites, cited references and vector diagrams. One of ordinary skill in the art would immediately recognize the obvious errors in the sequences of the Figures (as well as the original paper copy of the sequence listing) based upon the specification as-filed. The included paper copy of the Powerpoint presentation refers to U.S. 5,789,554 ("the '554 patent), the parent application of the present application and refers to the original specification, but applicants also refer to portions of the original application as filed. The Powerpoint addresses errors